共 15 条
[1]
Healing and relapse rates in gastroe-sophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole and pantoprazole compared with omeprazole , ranitidine and placebo: evidence from randomized clinical trials. Cam JJ. Clinical Therapeutics . 2001
[2]
Pantoprazole: a new proton-pump inhibitor in the treatment of upper gastrointesti- nal disease. Bardhan KD. Drugs of Today . 1999
[3]
Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Waldum HL,Brenna E,Sandvik AK. Expert Opin Drug Saf . 2002
[4]
Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Kwon D,Chae JB,Park CW,et al. Arzneimittelfors . 2001
[5]
Pharmacokinetic and Pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. Yu KS,Bae KS,Shon JH,et al. Clinical Pharmacology . 2004
[6]
The proton-pump inhibitors: similarities and differences. Horn J. Clinical Therapeutics . 2000
[7]
Highly effective twicedaily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance. Lerang F,Mourn B,Hang JB,et al. The American journal of Gastroenterology . 1997
[8]
Appropriate acid suppression for the management of gastroesophageal reflux disease. Bell NJV,Burget D.Howden CW,et al. Digestion, 1992, 51 (Supple 1) .
[9]
Pharmacologic properties of proton pump inhibitors. Welage LS. Pharmacotherapy . 2003
[10]
An overview of proton pump inhibitors. Der G. Gastroenterology Nursing . 2003